GlobeNewswire by notified

LEADERSHIP UPDATE AND CEO SUCCESSION

Share

LEADERSHIP UPDATE AND CEO SUCCESSION

Amsterdam, the Netherlands - Flow Traders N.V. (Euronext: FLOW) announces that Dennis Dijkstra has decided not toseekreappointmentas Chief Executive Officer and member of the Management Board. Mike Kuehnel, currentlyserving as Chief Financial Officer and member of the Management Board, will become Chief Executive Officer effective 1 February 2023.

Dennis Dijkstra has conveyed to the Supervisory Board his intention not to stand for reappointment to the Management Board at the 2023 Annual General Meeting. Dennis joined Flow Traders as Chief Financial Officer in 2009 and was first appointed Co-CEO in January 2014 and subsequently CEO in May 2019. He has been a member of the Management Board since Flow Traders’ IPO in 2015.

The Supervisory Board has unanimously decided that Mike Kuehnel will assume the role of Chief Executive Officer as of 1 February 2023. Mike was confirmed as a member of the Management Board and Chief Financial Officer in September 2021 having joined Flow Traders in August 2021. As Chief Financial Officer, Mike has been responsible for overseeing the Finance, Investor Relations and Tax functions, as well as the development of Flow Traders’ growth strategy. More recently, Mike has also been responsible for the Risk and Compliance functions. Mike has over twenty years of investment banking and strategy consulting experience in the global financial market infrastructure space.

In order to ensure an effective leadership transition, Dennis will hand over his responsibilities to Mike on 1 February 2023 and remain with Flow Traders in an advisory capacity until the end of April 2023. Mike, together with Folkert Joling, Chief Trading Officer and member of the Management Board, and in conjunction with the newly established global Executive Committee will focus on accelerating the execution of Flow Traders’ strategic growth agenda to create value for all stakeholders.

The Supervisory Board has initiated the search process for a new Chief Risk and Financial Officer.   

Rudolf Ferscha, Chairman of the Supervisory Board of Flow Traders, commented:
“On behalf of the Supervisory Board, I would like to express our deepest gratitude to Dennis for his fourteen years of dedicated service to Flow Traders and his significant contribution to driving the company to where it is today. Under Dennis’ entrepreneurial leadership, Flow Traders has become one of the world’s leading liquidity providers and completing the successful IPO in 2015 is one of the many highlights of his extensive tenure. Dennis can look back with exceptional pride on his time at Flow Traders and we wish him every success with his future endeavors. We are delighted that Mike will assume the roleof Chief Executive Officer. He will,alongside Folkert and the newly established Executive Committee,ensure the delivery of Flow Traders’ ambitious growth strategy.

Dennis Dijkstra, CEO of Flow Traders, added:
I am incredibly proud to have led Flow Traders since 2014 andto have had the ability to work with such vibrantcolleagues. Flow Traders has grown across geographies, asset classes and teams, with the company going from strengthtostrength on its journey to becominganext generation global liquidity provider. I am truly privileged to have been part of this incredible success story. I have the utmost confidence in the Management Board and Executive Committee to lead the business through its next phase of development. I would like to thank all the current and past Flow Traders colleagues; none of this would have been possible without them and it has been an absolute pleasure to have been part of the team.

Mike Kuehnel, CFO of Flow Traders, added:
“I am truly honored to be succeeding Dennis as CEO of Flow Traders and to lead this exceptionally talented global team. Flow Traders is a unique business with all the essential componentsin place to deliver on our ambitious strategic growth agenda. I am confident we can successfully leverage the numerous opportunities presented by the rapidly evolving financial markets.Naturally, I am delighted to be part of Flow Traders at such an exciting time and look forward to building a bright future with my passionate and talented colleagues.”

Contact Details

Flow Traders N.V.

Investors
Jonathan Berger
Phone:         +31 20 7996149
Email:        investor.relations@flowtraders.com

Media
Laura Peijs
Phone:         +31 20 7996125
Email:        press@flowtraders.com

About Flow Traders

Flow Traders is a leading global financial technology-enabled liquidity provider in financial products, historically specialized in Exchange Traded Products (ETPs), now expanding into other asset classes. Flow Traders ensures the provision of liquidity to support the uninterrupted functioning of financial markets. This allows investors to continue to buy or sell ETPs or other financial instruments under all market circumstances. We continuously grow our organization, ensuring that our trading desks in Europe, the Americas and Asia can provide liquidity across all major exchanges, globally, 24 hours a day. Founded in 2004, we continue to cultivate the entrepreneurial, innovative and team-oriented culture that has been with us since the beginning. Please visit www.flowtraders.com for more information.

Important Legal Information

This press release is prepared by Flow Traders N.V. and is for information purposes only. It is not a recommendation to engage in investment activities and you must not rely on the content of this document when making any investment decisions. The information in this document does not constitute legal, tax, or investment advice and is not to be regarded as investor marketing or marketing of any security or financial instrument, or as an offer to buy or sell, or as a solicitation of any offer to buy or sell, securities or financial instruments.

The information and materials contained in this press release are provided ‘as is’ and Flow Traders N.V. or any of its affiliates (“Flow Traders”) do not warrant the accuracy, adequacy or completeness of the information and materials and expressly disclaim liability for any errors or omissions. This press release is not intended to be, and shall not constitute in any way a binding or legal agreement, or impose any legal obligation on Flow Traders. All intellectual property rights, including trademarks, are those of their respective owners. All rights reserved. All proprietary rights and interest in or connected with this publication shall vest in Flow Traders. No part of it may be redistributed or reproduced without the prior written permission of Flow Traders.

This press release may include forward-looking statements, which are based on Flow Traders’ current expectations and projections about future events, and are not guarantees of future performance. Forward looking statements are statements that are not historical facts, including statements about our beliefs and expectations. Words such as “may”, “will”, “would”, “should”, “expect”, “intend”, “estimate”, “anticipate”, “project”, “believe”, “could”, “hope”, “seek”, “plan”, “foresee”, “aim”, “objective”, “potential”, “goal” “strategy”, “target”, “continue” and similar expressions or their negatives are used to identify these forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors because they relate to events and depend on circumstances that will occur in the future whether or not outside the control of Flow Traders. Such factors may cause actual results, performance or developments to differ materially from those expressed or implied by such forward-looking statements. Accordingly, no undue reliance should be placed on any forward-looking statements. Forward-looking statements speak only as at the date at which they are made. Flow Traders expressly disclaims any obligation or undertaking to update, review or revise any forward-looking statements contained in this press release to reflect any change in its expectations or any change in events, conditions or circumstances on which such statements are based unless required to do so by applicable law.

Financial objectives are internal objectives of Flow Traders to measure its operational performance and should not be read as indicating that Flow Traders is targeting such metrics for any particular fiscal year. Flow Traders’ ability to achieve these financial objectives is inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond Flow Traders’ control, and upon assumptions with respect to future business decisions that are subject to change. As a result, Flow Traders’ actual results may vary from these financial objectives, and those variations may be material.

Efficiencies are net, before tax and on a run-rate basis, i.e. taking into account the full-year impact of any measure to be undertaken before the end of the period mentioned. The expected operating efficiencies and cost savings were prepared on the basis of a number of assumptions, projections and estimates, many of which depend on factors that are beyond Flow Traders’ control. These assumptions, projections and estimates are inherently subject to significant uncertainties and actual results may differ, perhaps materially, from those projected. Flow Traders cannot provide any assurance that these assumptions are correct and that these projections and estimates will reflect Flow Traders’ actual results of operations.

By accepting this document you agree to the terms set out above. If you do not agree with the terms set out above please notify legal.amsterdam@nl.flowtraders.com immediately and delete or destroy this document.

Market Abuse Regulation

This press release contains information within the meaning of Article 7(1) of the EU Market Abuse Regulation.


Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

RevoluGROUP Announces CEO and Director Stepping Down3.5.2024 00:25:00 CEST | Press release

VANCOUVER, British Columbia and BARCELONA, Spain., May 02, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX- V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) ("RevoluGROUP") today announced CEO and Director, Gavin McMillan, will be stepping down from his positions, effective immediately. Gavin joined the Company in August 2023 and served as CEO for over six months. During his leadership, McMillan has been instrumental in focusing on the continued development of the API-driven Payment-as-a-Service (PaaS) model, which has continued to expand through key white-label partnerships and joint venture agreements and enhancing revenue streams. In a statement, Bernard Lonis, the Chairman of the Board, acknowledged McMillan's vital contributions and leadership, stating, "We owe a great deal of gratitude to Gavin for his dedication and the continued strong foundation he has helpedtobuildforRevoluGROUP'sfuture. We wish Gavin the best in his future endeavors." The Board has commenced a comprehensi

Novotech Appoints Commercial and Clinical Life Sciences Specialist to Head Up Global Drug Development Consulting Team2.5.2024 23:00:15 CEST | Press release

BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has appointed Scott Schliebner as Vice President and Global Head, Drug Development Consulting (DDC). Novotech’s Chief Medical Officer Dr. Judith Ng-Cashin stated: “We welcome Scott to the medical and scientific team. He is a proven strategic, innovative, and business focused life sciences executive with ~30 year of experience across the biopharma and CRO sectors. He brings valuable leadership to our world-class DDC team, a full-service global drug development and strategic regulatory team providing comprehensive "inception to approval" services.” The DDC partners with biotechs to optimize a fit-for purpose therapeutic development strategy that both advances the development program and creates value for the company. To do this, DDC leverages CMC/manufa

Brookfield Reinsurance Completes Acquisition of AEL2.5.2024 22:10:00 CEST | Press release

BROOKFIELD, NEWS, May 02, 2024 (GLOBE NEWSWIRE) -- Brookfield Reinsurance (NYSE, TSX: BNRE, BNRE.A) and American Equity Investment Life Holding Company (NYSE: AEL) (“AEL”) today announced the completion of Brookfield Reinsurance’s acquisition of AEL in a cash and stock transaction valued at $56.50 per AEL share. AEL’s leading fixed annuity business bolsters Brookfield Reinsurance’s expanding insurance operations and increases its insurance assets under management to over $100 billion. Jon Bayer, Managing Partner at Brookfield Reinsurance said, “We are excited to welcome AEL to our organization as we continue to grow, diversify and scale our retirement services capabilities. AEL’s strong franchise and track record of serving policyholders and distribution partners, coupled with the scale of our existing platform and offerings, will position us well for the next phase of growth.” Brookfield Reinsurance expects to maintain AEL’s headquarters in Des Moines, Iowa, and its growth in the fixe

Fortinet Reports First Quarter 2024 Financial Results2.5.2024 22:05:43 CEST | Press release

First Quarter 2024 Highlights Total revenue of $1.35 billion, up 7% year over yearService revenue of $944 million, up 24% year over yearGAAP operating margin of 23.7%Non-GAAP operating margin of 28.5%1Cash flow from operations of $830 millionFree cash flow of $609 million1 SUNNYVALE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Fortinet® (Nasdaq: FTNT), a global cybersecurity leader driving the convergence of networking and security, today announced financial results for the first quarter ended March 31, 2024. “We are diligently executing on our strategy announced six months ago to leverage our scale, go-to-market capabilities, customer-first focus, and engineering expertise to capitalize on the fast-growing Unified SASE and Security Operations markets while continuing to gain market share in Secure Networking,” said Ken Xie, Founder, Chairman and Chief Executive Officer of Fortinet. “We believe our Unified SASE offering is the most comprehensive in the industry and we are well-positioned

Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results2.5.2024 22:05:00 CEST | Press release

Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz PharmaceuticalsExpected initiation of a Phase 3 clinical trial for zanidatamab in the second half of 2024, for breast cancer patients who have progressed on trastuzumab deruxtecan (T-DXd), by our partner, Jazz Pharmaceuticals Two planned investigational new drug (IND) and foreign equivalent submissions in 2024 for ZW191 and ZW171Acceptance of an abstract for zanidatamab in BTC at the American Society of Clinical Oncology (ASCO) annual meeting submitted by our partner, Jazz PharmaceuticalsPresentation of five abstracts at the American Association for Cancer Research (AACR) ann

HiddenA line styled icon from Orion Icon Library.Eye